Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
05 January 2022 - 5:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2021
Commission File Number: 001-36815
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Tuborg
Boulevard 12
DK-2900 Hellerup
Denmark
(Address of
principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576,
333-254101, and 333-261550) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134, 333-225284 and
333-256571) of Ascendis Pharma A/S (the Company) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to
the extent not superseded by documents or reports subsequently filed or furnished.
Closing of Warrant Exercise Window
On December 30, 2021, an exercise window closed for the Companys outstanding warrants exercisable for the Companys ordinary shares, nominal
value DKK 1. In connection with the exercises of certain of such warrants during this exercise window, the Company registered aggregate share capital increases of nominal DKK 59,959 with the Danish Business Authority, corresponding to an
aggregate increase in the Companys share capital to nominal DKK 56,937,682 through the issuance of 59,959 ordinary shares against average cash consideration of approximately USD $43.99 per share, based on the DKK-USD exchange rate on December 30, 2021. The Companys articles of association were amended accordingly and are attached hereto as Exhibit 1.1.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Ascendis Pharma A/S
|
|
|
|
|
Date: January 4, 2022
|
|
|
|
By:
|
|
/s/ Michael Wolff Jensen
|
|
|
|
|
|
|
Michael Wolff Jensen
|
|
|
|
|
|
|
Senior Vice President, Chief Legal Officer
|
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Apr 2023 to Apr 2024